Market Closed -
Nasdaq
04:00:00 2024-06-10 pm EDT
5-day change
1st Jan Change
7.78
USD
+1.30%
+2.64%
+38.93%
SIGA Technologies, Inc.'s Equity Buyback announced on August 5, 2021, has expired with 4,152,118 shares, representing 5.69% for $28.49 million.
The company expired its plan on December 31, 2023.
Sector Update: Health Care Stocks Advance Late Afternoon
03:57pm
MT
Sector Update: Health Care
03:37pm
MT
Calidi Biotherapeutics Signs Virotherapy Deal With Siga Technologies -- Calidi Shares Surge Pre-Bell
08:15am
MT
Earnings Flash (SIGA) SIGA TECHNOLOGIES Reports Q1 Revenue $25.4M
May. 07
MT
Transcript : SIGA Technologies, Inc., Q1 2024 Earnings Call, May 07, 2024
May. 07
SIGA Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 07
CI
SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical
Apr. 01
MT
SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX
Apr. 01
CI
SIGA Technologies, Inc. Announces the Appointment of Larry Miller as General Counsel
Mar. 25
CI
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High
Mar. 13
DJ
Tranche Update on SIGA Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2021.
Mar. 12
CI
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
Transcript : SIGA Technologies, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Mar. 12
Sector Update: Health Care Stocks Rise Late Afternoon
Mar. 12
MT
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 12
CI
SIGA Technologies Share Rise After Special Cash Dividend Announcement
Mar. 12
MT
Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024
Mar. 12
CI
SIGA Technologies Names Diem Nguyen as Chief Executive
Jan. 22
MT
Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors
Jan. 22
CI
SIGA Technologies, Inc. Announces CEO Changes
Jan. 22
CI
SIGA Technologies, Inc.'s Equity Buyback announced on August 5, 2021, has expired with 4,152,118 shares, representing 5.69% for $28.49 million.
Dec. 30
CI
Stigma, regulatory barriers delay mpox response in country that needs it most
Dec. 05
RE
SIGA Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Earnings Flash (SIGA) SIGA TECHNOLOGIES Posts Q3 Revenue $9.2M
Nov. 07
MT
Transcript : SIGA Technologies, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.
More about the company
1st Jan change
Capi.
+38.93% 546M +48.39% 765B -6.13% 354B +20.61% 331B +10.00% 299B +18.87% 248B -1.96% 219B +11.11% 216B +5.80% 164B -2.50% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1